President Bill Clinton and two Ukrainian foundations, headed by Elena Franchuk and Victor Pinchuk, signed an agreement of cooperation today that will expand the work against HIV/AIDS in Ukraine.
Under the agreement Ukraine will receive access to the best practices to fight epidemics and the latest know-how in the area of HIV/AIDS prevention, treatment and care. The Elena Franchuk ANTIAIDS foundation will cooperate with Clinton HIV/AIDS Initiative for the next five years in implementing project aimed at reducing HIV/AIDS escalation, care and support of people living with HIV/AIDS in Ukraine. Elena Franchuk and Victor Pinchuk are contributing US$2.5 million toward the project.
The funds will be used during the next five years to pay for programs aimed at slowing the growth of new HIV/AIDS cases, as well as for treatment and support of people living with HIV/AIDS in Ukraine.
"I'm happy to be working with the Elena Franchuk ANTIAIDS Foundation and the Victor Pinchuk Foundation on expanding access to HIV/AIDS prevention, care and treatment services in Ukraine," President Clinton said. "Through their generous support, we will be able to greatly increase the number of people with access to these services, and I am grateful for the partnership."
"The work of Clinton Foundation made tremendous difference in treatment and care of people living with HIV/AIDS in many countries. I am sure that Ukraine will benefit from President Clinton's expertise," Elena Franchuk said. "For the ANTIAIDS Foundation this partnership means an expansion of our activities, which have been centered for the last three years on media campaigns. Now, to change the AIDS situation in Ukraine, the country needs the best international experience and know-how in combating the epidemics."
Work during the first year of the project will be centered on the Dnepropetrovsk region, in the southeast part of Ukraine, which is home to more than 3 million people. The program's initiatives will be replicated in other regions of Ukraine in following years.
Specifically, the programs will work to increase access to rapid testing, improve laboratory capacity, train and mentor health care workers, introduce HIV treatment/substitution therapy and to improve drug procurement processes. The program will also work nationally in Ukraine to expand HIV testing legislation, develop rapid HIV test guidelines, register methadone for use and improve distribution and drug procurement processes and prices.
The agreement is the result of discussions started in 2004, when representatives of The Clinton Foundation visited Ukraine at the invitation of Ms. Franchuk. Following that visit an agreement between the Clinton Foundation and the government of Ukraine was signed, which assisted the government in receiving access to the lowest prices on generic antiretroviral drugs for HIV/AIDS treatment. The agreement allowed more patients in Ukraine to receive access to live-saving therapy as part of the Global Fund to Fight AIDS, TB and Malaria grant.
The work continued in 2005 during President Clinton's visit to Ukraine, with the signing of a memorandum which identified priority directions of cooperation of Clinton Foundation and the Government of Ukraine in the fight against HIV/AIDS. The five year program resulted from that memorandum. The Elena Franchuk "ANTIAIDS" Foundation and the Victor Pinchuk Foundation expressed their readiness to join efforts in the implementation of this project and committed the US$2.5 million.
Wednesday, January 21, 2009
Former U.N. Special Envoy For HIV/AIDS In Africa Lewis Calls On Canada To Commit $855M To Global Fund
Stephen Lewis, former United Nations special envoy for HIV/AIDS in Africa, on Friday at a press conference called on the Canadian government to commit 900 million Canadian dollars, or about $855 million, during the next three years to the Global Fund To Fight AIDS, Tuberculosis and Malaria, the Toronto Star reports. Lewis also called on Canada's leaders to increase foreign aid contributions as part of the country's membership in the Group of Eight industrialized nations (Black, Toronto Star, 8/11).
Lewis at the press conference said that Canada is decreasing its financial aid commitments aimed at fighting HIV/AIDS in developing countries. Lewis said Canada is "going in reverse" in funding commitments, adding, "It's just delinquency to fall further behind" (CanWest/Calgary Herald, 8/11).
In addition, Lewis at the press conference released the results of a Canadian Coalition for Youth and HIV/AIDS in Africa poll. The poll found that 46% of respondents believe it is "very" important for the government to increase access to treatment for people living with HIV/AIDS in developing countries, while 45% found it "somewhat" important. The coalition - which includes Canadian chapters of CARE, Plan, Save the Children and World Vision - also called on the government to increase funding to fight HIV in developing countries.
According to the poll, nine out of 10 respondents believe HIV/AIDS is a serious problem, and 62% believe it is an international emergency. In addition, 48% of survey participants said the government is spending too little to fight HIV/AIDS in developing countries. Ninety percent of participants said Africa is the most vulnerable area worldwide to HIV/AIDS, and 92% understood that the continent is the hardest hit by the spread of the virus.
The poll also found that 70% of respondents believed they are well-informed about HIV/AIDS, compared with 80% in 2005. The poll was based on a sample of 1,429 adults and has a margin of error of plus or minus 2.6 percentage points, the Star reports (Toronto Star, 8/11).
Lewis at the press conference said that Canada is decreasing its financial aid commitments aimed at fighting HIV/AIDS in developing countries. Lewis said Canada is "going in reverse" in funding commitments, adding, "It's just delinquency to fall further behind" (CanWest/Calgary Herald, 8/11).
In addition, Lewis at the press conference released the results of a Canadian Coalition for Youth and HIV/AIDS in Africa poll. The poll found that 46% of respondents believe it is "very" important for the government to increase access to treatment for people living with HIV/AIDS in developing countries, while 45% found it "somewhat" important. The coalition - which includes Canadian chapters of CARE, Plan, Save the Children and World Vision - also called on the government to increase funding to fight HIV in developing countries.
According to the poll, nine out of 10 respondents believe HIV/AIDS is a serious problem, and 62% believe it is an international emergency. In addition, 48% of survey participants said the government is spending too little to fight HIV/AIDS in developing countries. Ninety percent of participants said Africa is the most vulnerable area worldwide to HIV/AIDS, and 92% understood that the continent is the hardest hit by the spread of the virus.
The poll also found that 70% of respondents believed they are well-informed about HIV/AIDS, compared with 80% in 2005. The poll was based on a sample of 1,429 adults and has a margin of error of plus or minus 2.6 percentage points, the Star reports (Toronto Star, 8/11).
Thai HIV/AIDS Advocates To Ask Administrative Court For Review Of Ruling That Found Abbott Did Not Violate Trade Laws
HIV/AIDS advocates in Thailand plan to ask the country's Administrative Court to evaluate an Internal Trade Department's decision to not file suit against Abbott Laboratories for allegedly violating trade laws when the company canceled the registration of its anti retro viral Aluvia with the country's Food and Drug Administration, the Bangkok Post reports (Apiradee, Bangkok Post, 1/18).
The Thai government in January 2007 issued a compulsory license to produce a lower-cost version of Abbott's anti re trivial Kaletra. The drug company in May 2007 offered to sell Aluvia, an updated version of Kaletra, at a reduced price in Thailand on the condition that the country agree not to allow generic versions of the drug into the market, Siriwat Thiptaradol, secretary-general of the Thai FDA, said. The Thai Ministry of Public Health in June 2007 confirmed that it would continue with its plan to issue a compulsory license for the drug after Abbott and the health ministry could not reach a price agreement during negotiations. Thailand's FDA in October 2007 completed the registration of a generic version of Aluvia for use under the country's compulsory licensing program. The generic version is manufactured by the Indian generic pharmaceutical company Matrix Laboratories .
According to HIV/AIDS advocates, Abbott canceled registration of Aluvia in Thailand after the government issued a compulsory license for the drug. Advocates have said the move violated section 25 of the country's Trade Competition Act, which stipulates restrictions against a product being dominant in the market.
In addition, the advocates said that the canceled registration violated section 28 of the trade act, which places controls on parent companies' influence on subsidiaries' decisions, the Post reports.
Advocates later petitioned a trade competition panel at the Ministry of Commerce to look into the matter. The panel in late December 2007 ruled that Abbott's withdrawal of Aluvia's registration did not violate trade regulations.
Panel secretary Yanyong Phuangrach said the body determined the market value of Aluvia was too small to dominant the market and thus did not violate trade law.
Saree Ongsomwang - manager of the Foundation for Consumers, which petitioned the ministry panel to examine the issue - said advocates would ask the Administrative Court to review the panel's decision. Nimit Tienudom, chair of the AIDS Access Foundation, petitioned the panel to reveal additional details about its decision. He also proposed that a new panel of neutral academics be convened to examine the issue. Saree said she was "surprised by the panel's decision," adding, "They should have prioritized health problems caused by HIV/AIDS and consider essential lifesaving drugs as a special case rather than protecting the benefits of big pharmaceutical business" (Bangkok Post, 1/18).
The Thai government in January 2007 issued a compulsory license to produce a lower-cost version of Abbott's anti re trivial Kaletra. The drug company in May 2007 offered to sell Aluvia, an updated version of Kaletra, at a reduced price in Thailand on the condition that the country agree not to allow generic versions of the drug into the market, Siriwat Thiptaradol, secretary-general of the Thai FDA, said. The Thai Ministry of Public Health in June 2007 confirmed that it would continue with its plan to issue a compulsory license for the drug after Abbott and the health ministry could not reach a price agreement during negotiations. Thailand's FDA in October 2007 completed the registration of a generic version of Aluvia for use under the country's compulsory licensing program. The generic version is manufactured by the Indian generic pharmaceutical company Matrix Laboratories .
According to HIV/AIDS advocates, Abbott canceled registration of Aluvia in Thailand after the government issued a compulsory license for the drug. Advocates have said the move violated section 25 of the country's Trade Competition Act, which stipulates restrictions against a product being dominant in the market.
In addition, the advocates said that the canceled registration violated section 28 of the trade act, which places controls on parent companies' influence on subsidiaries' decisions, the Post reports.
Advocates later petitioned a trade competition panel at the Ministry of Commerce to look into the matter. The panel in late December 2007 ruled that Abbott's withdrawal of Aluvia's registration did not violate trade regulations.
Panel secretary Yanyong Phuangrach said the body determined the market value of Aluvia was too small to dominant the market and thus did not violate trade law.
Saree Ongsomwang - manager of the Foundation for Consumers, which petitioned the ministry panel to examine the issue - said advocates would ask the Administrative Court to review the panel's decision. Nimit Tienudom, chair of the AIDS Access Foundation, petitioned the panel to reveal additional details about its decision. He also proposed that a new panel of neutral academics be convened to examine the issue. Saree said she was "surprised by the panel's decision," adding, "They should have prioritized health problems caused by HIV/AIDS and consider essential lifesaving drugs as a special case rather than protecting the benefits of big pharmaceutical business" (Bangkok Post, 1/18).
GeoVax Reports Progress On Its AIDS Vaccine Technology
GeoVax Labs, Inc. (OTC Bulletin Board: GOVX), an Atlanta based, publicly traded biopharmaceutical company specializing in the prevention and treatment of infectious diseases, provided an operational update on the company's progress towards entering Phase 2 preventative human clinical trial testing and plans to proceed into therapeutic human trials with its AIDS vaccine.
Five successful human trials evaluating GeoVax AIDS vaccines have previously been reported.
Planned Phase 2 Human Clinical Trial for Prevention of AIDS
The Company's Phase 2 trial, conducted by the U.S. National Institutes of Health (NIH) supported HIV Vaccine Trials Network (HVTN), will involve 225 healthy volunteers from the United States and South America, and will further evaluate the safety and immunogenicity of the GeoVax preventative vaccine (vaccine administered prior to infection with the HIV virus). In Phase 1 trials, both 1/10th dose and full dose of the GeoVax vaccine elicited anti-HIV T-cells, whereas the full dose was required to elicit good frequencies of antibody to the HIV Envelope glycoprotein. The larger Phase 2 human trial will broaden the base of safety and immunogenicity data for the full dose of the GeoVax AIDS vaccine with a view to protecting recipients from developing AIDS should they be exposed to the virus. The planned Phase 2 human clinical trial is currently scheduled to start early this fall, subject to FDA approval.
Preclinical Data for Use of Vaccine Technology as an AIDS Therapeutic Human Clinical Trials in Planning Stages GeoVax also announced summary data from a pilot study on therapeutic vaccination in simian immunodeficiency virus (SIV) infected non-human primates with the SIV prototype for the GeoVax AIDS vaccine. In this small pilot study, conducted by Dr. Amara at Emory University, two non-human primates were infected with SIV. At 12 weeks post SIV infection, conventional anti-viral drug therapy was given to the primates to reduce the viral RNA infection levels to very low levels creating a non progressor status for the primate. Then the SIV prototype vaccine for the GeoVax AIDS vaccine was administered. Six weeks following the final vaccination, anti-viral drug treatment was stopped and the animals were monitored to determine whether the vaccine could control the SIV infection during the absence of the drugs.
The outstanding results from the study revealed the vaccine controlling the infection in the absence of drugs. In one primate, the reduction in viral levels over pre-drug treatment and vaccination levels was 1000 times. In the other, the reductions in viral levels were 100 times. The excellent control of the virus infection in the absence of drug treatment was associated with the vaccine raising the types of CD4 and CD8 T cells that are found in the rare individuals who spontaneously control their HIV infections.
Based on these excellent results, planning for a therapeutic trial in infected and drug treated humans has been initiated. The intent of therapeutic vaccination is for the vaccine to "control" HIV virus levels in infected individuals to very low levels thus blocking the development of AIDS. Successful therapeutic AIDS vaccination programs with GeoVax vaccines would lead to reduction in the use of costly anti-HIV medications and their often harmful side effects.
Dr. Harriet Robinson, GeoVax Co-founder and Senior V.P. of Research and Development, commented, "I had not anticipated the extent of vaccine control that was achieved in the already infected non-human primates. These are highly promising results that need to be extended into infected humans to see if the vaccine can be used to reduce the need for taking drugs. The results also warrant more extended studies in already infected non-human primates to explore parameters that both limit and enhance the ability for a vaccine to displace the need for drugs."
Dr. Robert McNally, CEO and President of GeoVax Labs, Inc., emphasized, "It is noteworthy to mention that the GeoVax AIDS vaccines being tested in the preclinical therapeutic trial is the same basic vaccine administered in the Company's human trials testing for a preventative use of the vaccine, vaccinating people before infection to prevent the development of AIDS should they become infected. Thus, a "one for two" vaccine could be a breakthrough solution for the company and the world, saving millions of dollars in redundant development costs and years of testing time by utilizing safety data already achieved in Phase 1 preventative human trials. More important, time to market could be significantly reduced, saving lives much sooner than otherwise."
Further, GeoVax's management is pleased to report that the company is currently engaged in negotiations with a NIH sponsored trial network to administer, conduct and co-sponsor GeoVax's Therapeutic human trial program. Management expects to receive approval for undertaking formal protocol development in the near future and will report more detailed plans accordingly.
"From an operational standpoint, we are very pleased with the overall progress of the company," stated Dr. Robert McNally. "Progress with ongoing preventative vaccine trials and now the potential to address therapeutic use of the vaccine gives GeoVax an expanding role in the fight to control AIDS."
About GeoVax Labs, Inc.
GeoVax Labs, Inc. is a biotechnology company, established to develop, manufacture, license and commercialize human vaccines for diseases caused by HIV-1 (Human Immunodeficiency Virus) and other infectious agents. GeoVax's AIDS vaccine technology is the subject of 20 issued or filed patent applications. GeoVax AIDS vaccines are designed for use in uninfected people to prevent Acquired Immunodeficiency Disease (AIDS), caused by the virus known as HIV-1, should the person ever become infected. GeoVax AIDS vaccines also may be effective as therapeutics, treatment of people already infected with AIDS virus.
GeoVax's core AIDS vaccine technologies were developed by Dr. Harriet Robinson, Senior V.P. of Research and Development, through a collaboration of colleagues at Emory University's Vaccine Center, the National Institutes of Health (NIH), The Centers for Disease Control and Prevention (CDC) and GeoVax.
GeoVax AIDS vaccines have moved forward in human clinical trials conducted by the HIV Vaccine Trials Network (HVTN) based in Seattle, Washington. The HVTN, funded through a cooperative agreement with the National Institutes of Health (NIH), is the largest worldwide clinical trials program dedicated to the development and testing of AIDS vaccines. Preclinical work enabling evaluation of GeoVax DNA and MVA vaccines was funded and supported by NIAID, which provided additional support to GeoVax AIDS vaccine development program with a $15 million IPCAVD grant awarded in late 2007.
Safe Harbor Statement: All statements in this news release, not statements of historical fact, are forward-looking statements. These statements are based on expectations and assumptions on the date of this press release and are subject to numerous risks and uncertainties which could cause actual results to differ materially from those described in the forward-looking statements. Risks and uncertainties include, but are not limited to, whether: GeoVax can develop and manufacture these vaccines with the desired characteristics in a timely manner, GeoVax's vaccines will be safe for human use, GeoVax's vaccines will effectively prevent AIDS in humans, vaccines will receive regulatory approvals necessary to be licensed and marketed, GeoVax raises required capital to complete vaccine development, there is development of competitive products that may be more effective or easier to use than GeoVax's products, and other factors over which GeoVax has no control. GeoVax assumes no obligation to update these forward-looking statements, and does not intend to do so. Certain matters discussed in this news release are forward-looking statements involving certain risks and uncertainties including, without limitation, risks detailed in the Company's Securities and Exchange Commission filings and reports.
Five successful human trials evaluating GeoVax AIDS vaccines have previously been reported.
Planned Phase 2 Human Clinical Trial for Prevention of AIDS
The Company's Phase 2 trial, conducted by the U.S. National Institutes of Health (NIH) supported HIV Vaccine Trials Network (HVTN), will involve 225 healthy volunteers from the United States and South America, and will further evaluate the safety and immunogenicity of the GeoVax preventative vaccine (vaccine administered prior to infection with the HIV virus). In Phase 1 trials, both 1/10th dose and full dose of the GeoVax vaccine elicited anti-HIV T-cells, whereas the full dose was required to elicit good frequencies of antibody to the HIV Envelope glycoprotein. The larger Phase 2 human trial will broaden the base of safety and immunogenicity data for the full dose of the GeoVax AIDS vaccine with a view to protecting recipients from developing AIDS should they be exposed to the virus. The planned Phase 2 human clinical trial is currently scheduled to start early this fall, subject to FDA approval.
Preclinical Data for Use of Vaccine Technology as an AIDS Therapeutic Human Clinical Trials in Planning Stages GeoVax also announced summary data from a pilot study on therapeutic vaccination in simian immunodeficiency virus (SIV) infected non-human primates with the SIV prototype for the GeoVax AIDS vaccine. In this small pilot study, conducted by Dr. Amara at Emory University, two non-human primates were infected with SIV. At 12 weeks post SIV infection, conventional anti-viral drug therapy was given to the primates to reduce the viral RNA infection levels to very low levels creating a non progressor status for the primate. Then the SIV prototype vaccine for the GeoVax AIDS vaccine was administered. Six weeks following the final vaccination, anti-viral drug treatment was stopped and the animals were monitored to determine whether the vaccine could control the SIV infection during the absence of the drugs.
The outstanding results from the study revealed the vaccine controlling the infection in the absence of drugs. In one primate, the reduction in viral levels over pre-drug treatment and vaccination levels was 1000 times. In the other, the reductions in viral levels were 100 times. The excellent control of the virus infection in the absence of drug treatment was associated with the vaccine raising the types of CD4 and CD8 T cells that are found in the rare individuals who spontaneously control their HIV infections.
Based on these excellent results, planning for a therapeutic trial in infected and drug treated humans has been initiated. The intent of therapeutic vaccination is for the vaccine to "control" HIV virus levels in infected individuals to very low levels thus blocking the development of AIDS. Successful therapeutic AIDS vaccination programs with GeoVax vaccines would lead to reduction in the use of costly anti-HIV medications and their often harmful side effects.
Dr. Harriet Robinson, GeoVax Co-founder and Senior V.P. of Research and Development, commented, "I had not anticipated the extent of vaccine control that was achieved in the already infected non-human primates. These are highly promising results that need to be extended into infected humans to see if the vaccine can be used to reduce the need for taking drugs. The results also warrant more extended studies in already infected non-human primates to explore parameters that both limit and enhance the ability for a vaccine to displace the need for drugs."
Dr. Robert McNally, CEO and President of GeoVax Labs, Inc., emphasized, "It is noteworthy to mention that the GeoVax AIDS vaccines being tested in the preclinical therapeutic trial is the same basic vaccine administered in the Company's human trials testing for a preventative use of the vaccine, vaccinating people before infection to prevent the development of AIDS should they become infected. Thus, a "one for two" vaccine could be a breakthrough solution for the company and the world, saving millions of dollars in redundant development costs and years of testing time by utilizing safety data already achieved in Phase 1 preventative human trials. More important, time to market could be significantly reduced, saving lives much sooner than otherwise."
Further, GeoVax's management is pleased to report that the company is currently engaged in negotiations with a NIH sponsored trial network to administer, conduct and co-sponsor GeoVax's Therapeutic human trial program. Management expects to receive approval for undertaking formal protocol development in the near future and will report more detailed plans accordingly.
"From an operational standpoint, we are very pleased with the overall progress of the company," stated Dr. Robert McNally. "Progress with ongoing preventative vaccine trials and now the potential to address therapeutic use of the vaccine gives GeoVax an expanding role in the fight to control AIDS."
About GeoVax Labs, Inc.
GeoVax Labs, Inc. is a biotechnology company, established to develop, manufacture, license and commercialize human vaccines for diseases caused by HIV-1 (Human Immunodeficiency Virus) and other infectious agents. GeoVax's AIDS vaccine technology is the subject of 20 issued or filed patent applications. GeoVax AIDS vaccines are designed for use in uninfected people to prevent Acquired Immunodeficiency Disease (AIDS), caused by the virus known as HIV-1, should the person ever become infected. GeoVax AIDS vaccines also may be effective as therapeutics, treatment of people already infected with AIDS virus.
GeoVax's core AIDS vaccine technologies were developed by Dr. Harriet Robinson, Senior V.P. of Research and Development, through a collaboration of colleagues at Emory University's Vaccine Center, the National Institutes of Health (NIH), The Centers for Disease Control and Prevention (CDC) and GeoVax.
GeoVax AIDS vaccines have moved forward in human clinical trials conducted by the HIV Vaccine Trials Network (HVTN) based in Seattle, Washington. The HVTN, funded through a cooperative agreement with the National Institutes of Health (NIH), is the largest worldwide clinical trials program dedicated to the development and testing of AIDS vaccines. Preclinical work enabling evaluation of GeoVax DNA and MVA vaccines was funded and supported by NIAID, which provided additional support to GeoVax AIDS vaccine development program with a $15 million IPCAVD grant awarded in late 2007.
Safe Harbor Statement: All statements in this news release, not statements of historical fact, are forward-looking statements. These statements are based on expectations and assumptions on the date of this press release and are subject to numerous risks and uncertainties which could cause actual results to differ materially from those described in the forward-looking statements. Risks and uncertainties include, but are not limited to, whether: GeoVax can develop and manufacture these vaccines with the desired characteristics in a timely manner, GeoVax's vaccines will be safe for human use, GeoVax's vaccines will effectively prevent AIDS in humans, vaccines will receive regulatory approvals necessary to be licensed and marketed, GeoVax raises required capital to complete vaccine development, there is development of competitive products that may be more effective or easier to use than GeoVax's products, and other factors over which GeoVax has no control. GeoVax assumes no obligation to update these forward-looking statements, and does not intend to do so. Certain matters discussed in this news release are forward-looking statements involving certain risks and uncertainties including, without limitation, risks detailed in the Company's Securities and Exchange Commission filings and reports.
Monday, December 22, 2008
Oral sex and risk-AIDS
What is the relationship? - You ask. It turns out that quite a! At least so believe scientists from UCLA Dental Institute (USA). They held a special laboratory study and its results published in the Journal of Acquired Immune Deficiency Syndromes at the beginning of December 2004.
The purpose of the experimental work was to study the influence of alcohol on the susceptibility of culture cells, mucous membrane lining of the mouth, to the Human Immunodeficiency Virus (HIVE). To do so from the mucosa of the oral cavity of HIVE patients uninfected cells kept for 10 minutes at 4% ethanol (similar to the content of alcohol in the most popular among Americans alcoholic beverages - beer) and then subjected to HIVE. It turned out that alcohol-treated epithelial cells of mucous membrane of the mouth were 3-6 times more susceptible to HIVE than cells that are not affected by alcohol.
It is these results have allowed the head of the study, Dr. June-wing Ghent concluded that consumption of alcohol, even in traditional American and previously considered to be "harmless" concentration, significantly increases the risk of HIVE infection with oral sex.
The originality of this pilot study is that researchers tried to find the specific mechanism of HIVE infection in modern society, in which oral sex "heated" Alcohol has long been no surprise.
The problem of AIDS once again seen by scientists
Since the detection of the world's first AIDS patient in 1981 in the scientific world, not rage disputes over how the same experience this disease. At one time in the post-Soviet space was quite popular version, that AIDS arose in the laboratories of American scientists who worked on the order of the CIA and the Pentagon. Subsequently, it turned out that this myth was artificially born purely for political reasons. It should be noted that the U.S. has never promoted version of that virus was developed by Russian scientists on whose orders or, as the basic version of the emergence of AIDS was recognized as the one on which this horrible disease we inherited a legacy of monkeys.
Currently known two types of AIDS virus. It is believed that one goes from green monkeys, and another - from anthropoid apes are likely orangutan. As of today in the scientific world leads people first became infected by a virus, then mutated into AIDS in 40-50th of the last century in countries such as Cameroon, Equatorial Guiana, Congo and the Central African Republic, where local residents have traditionally hunted on the monkeys and use their meat for food.
Recently, however, in the scientific world there were reports that questioned the accepted version of the emergence of AIDS. For example, with a rather exotic hypothesis made in the press group of scientists from the University of Melbourne. In their view, the AIDS virus came to Europe as a result of transfers aging rich testicles infected African chimpanzees. Such transplants with a view to rejuvenating practiced in France, Switzerland and Portugal.
Less exotic, but a scientific hypothesis put forward by the International Conference on Virology in Sydney, American specialists. They reported that the AIDS virus has been detected in the frozen tissues of people who died more than 30 years ago in the hospital of SST. Louis. They confidently stated that a comparative study of the virus 30 years ago and the current forms, can say that the virus mutated in the human body long before the outbreak of the disease in Africa, perhaps for hundreds of years. This discovery calls into question the old theory of the origin of the virus from African monkeys. Who knows, maybe after some time, scientists will prove that AIDS infection is much older than the accepted thinking, and that, for example, the dinosaurs became extinct it was from AIDS.
AIDS and human
One of the biggest shocks of our time is the emergence and rapid spread of "disease Century" - AIDS. Today the name of this virus is not gone from the pages of newspapers, TV and sound with radios: in our country faced the problem of disposable syringes, make demands polls checking with AIDS, set up various funds to fight the virus and allocated huge sums of money to inspect and search medications. In other countries made similar studies, and so far the AIDS virus studied very well, but a vaccine against it could not be found. Recently, some Western scientists studying AIDS (human immunodeficiency virus), are not so much finding a vaccine, but rather explore the causes of the devastating effects of the virus in the human immune system. The properties of human blood, including the features available on individual species and racial groups. Perhaps as a result of these studies will find answers to the concerns of our questions: - Why only a small fraction of infected fall ill and die? - How are based on racial origin DIG sick? - Why did the bulk of sick and the dead are in Africa and the USA? This raises another, at first sight paradoxical, but a very important question: Is AIDS a real danger to our people?The South African weekly "Patriot" reports that some data from several studies of Western scholars, suggesting that AIDS is acting strictly selective and destroys the immune system, resulting in the deaths of only those people whose veins runs the blood type of black people. That is, AIDS is a danger only to blacks, mulatto, Jews and Roma representatives whites kinds of people can be carriers of AIDS, but never ill if their immune system is not weakened by outside influences (drug addiction, alcoholism, homosexuality, etc.). This hypothesis is based on the fact that the blood of black and white type of people varies greatly in their qualities of immunological and biochemical indicators. When you mix black and white type of people (even through the centuries and generations) remains black blood biochemical indicators. This was demonstrated as far back as 1925 by soviet scientists who discovered the chemical reaction that gives the opportunity to find racial differences in blood. During the experiment, they took the blood of Russians (type of white people) and Jewish blood (black and white hybrid), produced from each response and got different results. This reaction identified Jews in 91.7% of all cases, that is enough for scientific and forensic evidence. All this allows to argue about the biochemical difference between Russian and Jewish blood. On the racial specificity of certain diseases, wrote in the 20's of the famous Soviet scientist BAN Peevishness (in his works dealt with, in particular malaria). Scientific studies have refuted demand proverb - "the blood of all the same - red. Blood is different for different types of people.
Our blood, the blood of white people, not such as the blood of blacks, mulatto and Jews. And should the hypothesis is confirmed, we can not be afraid of AIDS and boldly argued: AIDS is not dangerous white PEOPLE! Examples of indirectly supporting this hypothesis, many of them. Take the least sensational story with children, infected in children's hospitals city Alistair. The newspapers he predicted quick death, demanding placed in isolation. Who knows how much emotional pain experienced mother, listening to tales of mortal danger to their children and feeling ill of others? But time has passed, children grows up, strengthened and now his joyous laughter destroys the myth about AIDS. Nominated hypothesis Western researchers claimed: "danger to our health is not" But under the influence of public relations, many color, not knowing about these studies are afraid of AIDS.
Subscribe to:
Posts (Atom)